CCR6, known to be expressed on Th17 cells, was reduced to very low levels on Vδ1 cells in new-MS PBMC, consistent with negligible levels of IL-17, low RORγt, and an elevated IFN-γ expression. Here, IL17A is linked to myeloid sarcoma.